Indivior axes schizophrenia drug and shrinks revenue guidance
Indivior’s shares $INDV have lost nearly a third of their value this week, following the company’s announcement Tuesday that it was shelving a schizophrenia drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.